Renal Cancer

High-Dose Interleukin-2 Treatment Effective for Some Patients

Published in Cancer Weekly, April 4th, 2000

High-dose interleukin-2 treatment can add years to the lives of some patients with metastatic renal cell carcinoma, according to a study update.

"Recombinant IL-2 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every eight hours for up to 14 consecutive doses over five days as clinically tolerated with maximal support" in the original study, last updated in December 1998, explained R.I. Fisher and colleagues at Loyola University ("Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma," Cancer Journal from Scientific American, 2000;6(Suppl. 1):S55-S57).

This treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry